Studies with comparable HLA-G quantification methods differed considerably in the percentage of HLA-G-positive tumour samples (Engels et al. vs. De Kruijf et al. in breast carcinoma [20,21]; Lin et al. and Guo et al. vs. Zeestraten et al. in CRC [26,29,30]; Lin et al. vs. Yie et al. in ESCC [32,33]; Du et al. vs. Yie et al. in GC [35,40]; Lin et al. vs. Yie et al. in NSCLC [43,45]; Gonçalves et al. vs. Imani et al. in oral carcinoma [47,48]; Babay et al. vs. Andersson et al. in ovarian carcinoma [50,51]). This evidence concerns the gene HLA-G and breast carcinoma.